Please login to the form below

Not currently logged in
Email:
Password:

amyloidosis

This page shows the latest amyloidosis news and features for those working in and with pharma, biotech and healthcare.

Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

The protein, which is called transthyretin (TTR), can become abnormal in ATTR amyloidosis and break apart into smaller pieces (amyloid). ... for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is

Latest news

  • AstraZeneca and Ionis sign $3.6bn deal for eplontersen AstraZeneca and Ionis sign $3.6bn deal for eplontersen

    The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition. ... Eplontersen has the potential to halt the progression of TTR-mediated amyloidosis irrespective of

  • Pfizer's 2021 revenue predictions soar to $82bn Pfizer's 2021 revenue predictions soar to $82bn

    In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased

  • AZ buys Caelum Biosciences for $500m AZ buys Caelum Biosciences for $500m

    $350m. CAEL-101 is a potential first-in-class monoclonal antibody for the treatment of light chain (AL) amyloidosis. ... Standard treatment for AL amyloidosis is chemotherapy combined with thalidomide and/or steroids, which is effective but can kill the

  • Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

    Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy, an underdiagnosed and potentially fatal form of ATTR amyloidosis. ... Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which

  • Alnylam scores EU approval for RNAi drug Givlaari Alnylam scores EU approval for RNAi drug Givlaari

    Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.

More from news
Approximately 4 fully matching, plus 40 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wave Healthcare Communications

Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...